Artificial Intelligence in Drug Discovery Market by Offering (Software, Service), Application (Target Discovery, Lead Identification, Clinical Testing), Therapy Area (Oncology, Cardiology, Neurodegenerative), Deployment, End User-Global Forecast to 2030

Description

List of Tables

Artificial Intelligence in Drug Discovery Market Size, Share, Forecast, & Trends Analysis by Offering (Software, Service), Application (Target Discovery, Testing), Therapy Area (Oncology, Cardiology), Deployment, End User-Global Forecast to 2030

The global artificial intelligence in drug discovery market is projected to reach $8.95 billion by 2030 at a CAGR of 27.2% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.

The growth of this market can be attributed to the rising focus on reducing turnaround time in drug discovery, growing applications of AI in drug discovery, rising prevalence of chronic diseases, and rising collaborations & partnerships to accelerate the process of drug discovery and development. The constrained resource availability for integrating AI into drug discovery poses a significant impediment to market expansion in this sector.

Moreover, the growth of emerging economies and increased investments in research & development are anticipated to create lucrative opportunities for stakeholders in this market. However, limited availability of data sets are major challenges impacting market growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2023). The key players operating in the global artificial intelligence in drug discovery market are Microsoft Corporation (U.S.), Exscientia plc (U.K.), NVIDIA Corporation (U.S.), Schrodinger, LLC (U.S.), Atomwise, Inc. (U.S.), BenevolentAI Limited (U.K.), Deep Genomics Incorporated (Canada), InSilico Medicine (U.S.), Cloud Pharmaceuticals, Inc. (U.S.), and Standigm Inc. (South Korea).

Among all the offerings studied in this report, in 2023, the software segment is expected to account for the largest share of the AI in drug discovery market. AI in drug discovery software is used for faster, efficient, and cost-effective drug discovery and enhanced clinical trials. Thus, the growing interest of pharmaceutical companies in developing novel therapies has increased the adoption of AI in drug discovery software.

Among all the deployment modes studied in this report, the cloud-based segment is projected to register the highest CAGR over the forecast period. The demand for cloud-based and web-based platforms is growing due to the benefits of cloud-based models in terms of security, flexibility, high-capacity data storage, quick accessibility, and cost-effectiveness.

Among all the therapeutic areas studied in this report, in 2023, the oncology segment is expected to account for the largest share of the global AI in drug discovery market. Numerous collaborations between drug discovery and AI companies are bolstering the significant market share of this segment. For instance, in November 2022, The University of Texas MD Anderson Cancer Center (U.S.) and Exscientia plc (U.K.) entered a strategic collaboration to combine the drug discovery & development expertise of MD Anderson with the patient-centric artificial intelligence (AI) capabilities of Exscientia, to boost the development of novel small-molecule oncology therapies. Additionally, in November 2021, Sanofi (France) announced an equity investment of USD 180 million in Owkin (U.S.), an AI and precision medicine company, aimed at advancing its oncology pipeline.

Among all the applications studied in this report, in 2023, the lead compound identification segment is expected to account for the largest share of the global AI in drug discovery market. Identifying lead compounds is a pivotal stage in drug discovery, where crucial properties like selectivity and potency are determined before advancing to clinical studies. Integrating AI can streamline pre-clinical development timelines, optimizing resource allocation effectively. Therefore, the utilization of AI in this phase of drug discovery is pivotal, contributing significantly to the large market share of this sector.

Among all end users studied in this report, in 2023, the pharmaceutical & biopharmaceutical companies segment is expected to account for the largest share of the global AI in drug discovery market. The high prevalence of chronic and infectious diseases, high pressure on the pharmaceutical, and biotechnology companies, to bring effective therapies early to the market, and combined benefits of AI algorithms in facilitating smooth drug discovery processes are key factors contributing to the significant market share of this segment.

An in-depth analysis of the geographical scenario of the global artificial intelligence in drug discovery market provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle-East & Africa), along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the artificial intelligence in drug discovery market. In North America, in 2023, the U.S. is expected to account for the largest share of the artificial intelligence in drug discovery market. The large share of this regional market is attributed to increasing public and private investments in drug discovery, and the high adoption of AI solutions in drug discovery. The presence of key AI companies and pharmaceutical companies such as Abbott Laboratories (U.S) and Pfizer Inc. (U.S) also support the large share of this market.

Scope of the Report:

Artificial Intelligence in Drug Discovery Market Assessment-by Offering

Software
Services

Artificial Intelligence in Drug Discovery Market Assessment-by Deployment Mode

On-premises
Cloud & Web-based Mode

Artificial Intelligence in Drug Discovery Market Assessment-by Application

Target Discovery & Validation
Lead Compound Identification
De Novo Design and Drug Optimization
Preclinical & Clinical Testing

Artificial Intelligence in Drug Discovery Market Assessment-by Therapeutic Area

Oncology
Neurodegenerative Diseases
Cardiovascular Diseases
Metabolic Diseases
Other Therapeutic Areas

Note: Other therapeutic areas include infectious diseases and rare diseases.

Artificial Intelligence in Drug Discovery Market Assessment-by End Users

Pharmaceutical & Biopharmaceutical Companies
Contract Research Organizations (CROs)
Academic & Research Institutes

Artificial intelligence in Drug Discovery Market Assessment-by Geography

North America
U.S.
Canada
Europe
Germany
France
U.K
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle-East & Africa

Product Code: MRHC - 104745

1. Introduction

1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Process
2.2. Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research
2.3. Market Assessment
- 2.3.1. Market Size Estimation
  - 2.3.1.1. Bottom-up Approach
  - 2.3.1.2. Top-down Approach
  - 2.3.1.3. Growth Forecast
- 2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study

3. Executive Summary

4. Market Insights

4.1. Introduction
4.2. Drivers
- 4.2.1. Rising Focus on Reducing Turnaround Time in Drug Discovery
- 4.2.2. Growing Applications of AI in Drug Discovery
- 4.2.3. Rising Incidences of Chronic Diseases
- 4.2.4. Rising Collaborations and Partnerships to Accelerate the Drug Discovery and Development
4.3. Restraints
- 4.3.1. Limited Availability of Resources for Integration of AI in Drug Discovery
4.4. Opportunity
- 4.4.1. Emerging Economies
- 4.4.2. Rise in the Investments for R&D
4.5. Challenges
- 4.5.1. Limited Availability of Data Setss
4.6. Impact of COVID-19 on the AI in Drug Discovery Market

5. Global AI in Drug Discovery Market, by Offering

5.1. Introduction
5.2. Software
5.3. Services

6. Global AI in Drug Discovery Market, by Deployment Mode

6.1. Introduction
6.2. Cloud & Web-based Mode
6.3. On-premises Mode

7. Global AI in Drug Discovery Market, by Application

7.1. Introduction
7.2. Target Discovery & Validation
7.3. Lead Compound Identification
7.4. De Novo Design & Drug Optimization
7.5. Preclinical & Clinical Testing

8. Global AI in Drug Discovery Market, by Therapeutic Area

8.1. Introduction
8.2. Oncology
8.3. Neurodegenerative Diseases
8.4. Cardiovascular Diseases
8.5. Metabolic Diseases
8.6. Other Therapeutic Areas

9. Global AI in Drug Discovery Market, by End User

9.1. Introduction
9.2. Pharmaceutical & Biotechnology Companies
9.3. Contract Research Organizations (CROs)
9.4. Academic & Research Institutes

10. AI in Drug Discovery Market, by Geography

10.1. Introduction
10.2. North America
- 10.2.1. U. S.
- 10.2.2. Canada
10.3. Europe
- 10.3.1. Germany
- 10.3.2. France
- 10.3.3. U.K.
- 10.3.4. Italy
- 10.3.5. Spain
- 10.3.6. Rest of Europe
10.4. Asia-Pacific
- 10.4.1. China
- 10.4.2. Japan
- 10.4.3. India
- 10.4.4. Rest of Asia-Pacific
10.5. Latin America
- 10.5.1. Brazil
- 10.5.2. Mexico
- 10.5.3. Rest of Latin America
10.6. Middle East & Africa

11. Competitive Landscape

11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2022)

12. Company Profiles (Business Overview, Financial Overview, Solutions Portfolio, and Strategic Developments)

12.1. Microsoft Corporation
12.2. Exscientia plc
12.3. NVIDIA Corporation
12.4. Schrodinger, LLC
12.5. Atomwise, Inc.
12.6. BenevolentAI Limited
12.7. Deep Genomics Incorporated
12.8. InSilico Medicine
12.9. Cloud Pharmaceuticals, Inc.
12.10. Standigm Inc.

13. Appendix

13.1. Questionnaire
13.2. Available Customization